Personalized Lung Cancer Vaccine Trials: What Researchers Are Testing

Start with what these are not

No personalized lung cancer vaccine is approved by the FDA. None is available at a regular oncology clinic. Every one of them is being tested.

NCI lists only two treatment vaccines with FDA approval, and neither is for lung cancer. One treats some men with advanced prostate cancer. The other treats some people with melanoma. Everything in the lung cancer space is still in trials.

What a personalized vaccine is made of

Tumor cells carry mutations. Some mutations produce proteins that healthy cells never make. Researchers call those neoantigens.

The idea is to show those proteins to the immune system on purpose. A tumor sample is sequenced. A short list of targets is picked. A product is built for that one person and given as a series of doses.

Because each tumor differs, each product differs. That is what personalized means here. It is not a stronger version of an existing drug.

One trial, read line by line

A study called PNeoVCA shows what this looks like in practice. Its registry record lists these facts.

• It is a phase 1 and phase 2 study.
• It tests a personalized neoantigen peptide vaccine, alone and with the immunotherapy drug pembrolizumab.
• The stated aim is safety and tolerability.
• Planned enrollment is 132 people.
• It enrolls people with advanced solid tumors, and non-small cell lung cancer is one of the tumor types listed.

Note what is missing. There is no randomized comparison against standard care. Safety comes first, not survival. And lung cancer shares the trial with many other cancers.

Why the phase matters

A phase 1 study asks whether a treatment can be given safely and at what dose. A phase 2 study asks whether there is any signal of activity. Neither is designed to prove that people live longer.

That is not a flaw. It is the order the work has to happen in. But it means a headline about a lung cancer vaccine is usually reporting a safety study, not a treatment result. Our guide to joining a clinical trial explains what each phase commits you to.

What has been shown elsewhere

The strongest published results for personalized neoantigen vaccines have come from other cancers. NCI reported on two trials in 2025, in pancreatic and kidney cancer, given after surgery.

Those trials enrolled 16 and 9 people. Some participants stayed cancer-free for more than three years. Both trials were small, and neither had a control group. The researchers said larger trials are needed to confirm the findings.

Lung cancer is not the same disease. Results do not transfer between cancer types on their own.

Why researchers keep trying in lung cancer

Lung tumors, especially in people with a smoking history, often carry many mutations. More mutations mean more possible neoantigens. Lung cancer is also one of the cancers where immunotherapy already has a track record, so there is a partner treatment to combine with.

That reasoning is sound. It is still reasoning, not evidence.

The practical barriers

• Enough tumor tissue must be available to sequence.
• Building a product takes weeks, and the cancer does not pause.
• Trials run at a small number of centers.
• Travel, time off work, and extra visits fall on the participant.

Questions before you enroll

• What phase is this trial, and what is its main measure?
• Will I get the vaccine, or could I be assigned to something else?
• What treatment would I get if I did not join?
• How much tissue do you need, and do you already have it?
• How many visits, and where?

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

The National Cancer Information Foundation publishes Cancer Explained. This page is for learning. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.